FrancophonIA/ELRC3.0 huggingface dataset:
English: Common reactions were inappropriate urination, lethargy, alopecia (hair loss), panting, vomiting, decreased appetite, anorexia, decreased activity, depression, diarrhoea, polyphagia (excessive eating), shaking, tiredness and urinary tract infections.
Croatian: Česte reakcije bile su neprilično mokrenje, letargija, alopecija (gubitak dlake), dahtanje, povraćanje, smanjeni apetit, anoreksija, smanjenje aktivnosti, depresija, proljev, polifagija (pretjerano konzumiranje hrane), drhtanje, umor i upale mokraćnih puteva.
English: • Hypokalaemia, hypernatremia or Na⁺/K⁺ ratio > 32: Decrease the Zycortal dose.
Croatian: • Hipokalemia, hipernatremija ili omjer Na⁺/K⁺ > 32: smanjite dozu Zycortala:
English: Prolonging the dosing interval:
Croatian: Produljivanje intervala između doza:
English: Use with caution when administering Zycortal concurrently with medicinal products which affect either serum sodium or potassium concentrations, or cellular transportation of sodium or potassium, for example: trimethoprim, amphotericin B, digoxin or insulin.
Croatian: Budite oprezni kada dajete Zycortal istovremeno s medicinskim proizvodima koji djeluju na koncentracije serumskog natrija ili kalija, ili prijenos natrija ili kalija kroz stanične membrane, na primjer: trimetoprim, amfotetricin B, digoksin ili inzulin.
English: Continue 2.2 mg/kg body weight
Croatian: Nastavite s 2,2 mg/kg tjelesne težine
English: Interim monitoring visit:
Croatian: Kontrolni pregled:
English: In the clinical trial, the mean final dose of Zycortal was 1.9 mg/kg (range 1.2-2.5 mg/kg) and the mean final dosing interval was 38.7 ± 12.7 days (range 20-99 days) with the majority of dogs having a dosing interval between 20 and 46 days.
Croatian: U kliničkom ispitivanju, prosječna krajnja doza Zycortala bila je 1,9 mg/kg (raspon 1,2-2,5 mg/kg) i prosječni krajnji interval doziranja bio je 38,7 ± 12,7 dana (raspon 20-99 dana) s time da je većina pasa imala interval doziranja između 20 i 46 dana.
English: Prolonged-release suspension for injection.
Croatian: Suspenzija za injekcije s produljenim oslobađanjem.
English: In the clinical trial, the mean final dose of desoxycortone pivalate was 1.9 mg/kg (range 1.22.5 mg/kg) and the mean final dosing interval was 38.7 ± 12.7 days (range 20-99 days) with the majority of dogs having a dosing interval between 20 and 46 days.
Croatian: U kliničkom ispitivanju, prosječna krajnja doza dezoksikorton pivalata bila je 1,9 mg/kg (raspon 1,22,5 mg/kg) a prosječni krajnji interval doziranja bio je 38,7 ± 12,7 dana (raspon 20-99 dana) s time da je većina pasa imala interval doziranja između 20 i 46 dana.
English: Prolonged-release suspension for injection
Croatian: Suspenzija za injekcije s produljenim oslobađanjem
English: Excipients: Chlorocresol 1 mg/ml
Croatian: Pomoćne tvari: Klorokrezol 1 mg/ml
English: In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Croatian: U slučaju nehotičnog samo injiciranja, odmah potražite pomoć liječnika i pokažite mu uputu o VMP ili etiketu.
English: If irritation occurs, seek medical advice immediately and show the package leaflet or the label to the physician.
Croatian: Ako dođe do nadražaja, odmah potražite savjet liječnika i pokažite mu uputu o VMP ili etiketu.
English: • If the dog is either not clinically normal or if the Na⁺/K⁺ ratio is abnormal on Day 25, adjust the dose of glucocorticoid or Zycortal (see Subsequent doses and long term management).
Croatian: • Ako pas nema normalno kliničko stanje ili je omjer Na⁺/K⁺ poremećen na 25. dan, prilagodite dozu glukokortikoida ili Zycortala (vidi Naredne doze i dugotrajni režim).
English: Decrease dose to: 2.1 mg/kg body weight
Croatian: Smanjite dozu na: 2,1 mg/kg tjelesne težine
English: • If the dog is clinically normal and has a Na⁺/K⁺ ratio > 32 on Day 25, either adjust the dose based on the Day 10 Na⁺/K⁺ ratio according to Table 1 or delay the dose (see Prolonging the dosing interval).
Croatian: • Ako je kliničko stanje psa normalno i ima omjer Na⁺/K⁺ > 32 na 25. dan, onda ili prilagodite dozu na temelju omjera Na⁺/K⁺ na 10.dan u skladu s Tabelom 1 ili odgodite dozu (vidi Produživanje intervala između doza).
English: VIAL LABEL
Croatian: ETIKETA NA BOČICI
English: 4.9 Amounts to be administered and administration route
Croatian: 4.9 Količine koje se primjenjuju i put primjene Potkožna primjena.
English: ANNEX I
Croatian: DODATAK 1
English: desoxycortone pivalate 25 mg/ml
Croatian: dezoksikorton pivalat 25 mg/ml
English: PACKAGE LEAFLET: Zycortal 25 mg/ml prolonged-release suspension for injection for dogs
Croatian: UPUTA O VMP: Zycortal 25 mg/ml suspenzija za injekciju s produljenim oslobađanjem za pse
English: Active substance: Desoxycortone pivalate 25 mg/ml
Croatian: Djelatna tvar: Dezoksikorton pivalat 25 mg/ml
English: ratio (i.e. 27 to 32) on Day 25, adjust the dose based on the Day 10 Na⁺/K⁺ ratio using the guidelines in Table 1, below.
Croatian: (npr. 27 do 32) na 25. dan, prilagodite dozu na temelju
English: Increase dose to: 2.3 mg/kg body weight Increase dose to: 2.4 mg/kg body weight
Croatian: Povećajte dozu na: 2,4 mg/kg tjelesne težine
English: Zycortal 25 mg/ml prolonged-release suspension for injection for dogs
Croatian: Zycortal 25 mg/ml suspenzija za injekciju s produljenim oslobađanjem za pse
English: 25 days after the first dose, administer Zycortal, as follows: Decrease dose to: 2.0 mg/kg body weight
Croatian: 25 dana nakon prve doze, primijenite Zycortal, na sljedeći način:
English: • If the dog is both clinically normal and has a normal Na+/K+ ratio (i.e. 27 to 32) on Day 25, adjust the dose based on the Day 10 Na⁺/K⁺ ratio using the guidelines in Table 1, below.
Croatian: • Ako je kliničko stanje psa normalno i ima omjer Na⁺/K⁺ > 32 na 25. dan, onda ili prilagodite dozu na temelju omjera Na⁺/K⁺ na 10. dan u skladu s Tabelom 1 ili odgodite dozu (vidi Produljivanje intervala doziranja).
English: Zycortal 25 mg/ml prolonged-release suspension for injection for dogs desoxycortone pivalate
Croatian: Zycortal 25 mg/ml suspenzija za injekcije s produljenim oslobađanjem za pse dezoksikorton pivalat
English: Zycortal 25 mg/ml prolonged-release suspension for injection desoxycortone pivalate
Croatian: Zycortal 25 mg/ml suspenzija za injekcije s produljenim oslobađanjem dezoksikorton pivalat
English: The response was unknown in the remaining 13 patients.
Croatian: Odgovor nije bio poznat u preostalih 13 bolesnika.
English: Fifty of the patients in this study survived.
Croatian: Pedeset bolesnika u ovom ispitivanju je preživjelo.
English: It is given as an infusion over 15 minutes.
Croatian: Primjenjuje se kao infuzija tijekom 15 minuta.
English: Symptoms of brain damage resolved in 38 of 66 patients.
Croatian: Simptomi oštećenja mozga uklonjeni su kod 38 od 66 bolesnika.
English: The maximum total dose is 10 g for adults, and 140 mg/kg in children up to a maximum of 10 g.
Croatian: Maksimalna ukupna doza je 10 g za odrasle osobe, i 140 mg/kg u djece do maksimalno 10 g.
English: The second dose is given over a period of between 15 minutes and two hours, depending on the patient's condition.
Croatian: Druga se doza primjenjuje u razdoblju između 15 minuta i dva sata ovisno o stanju bolesnika.
English: The information on these patients was obtained from their medical notes, as recorded in databases at two French hospitals.
Croatian: Informacije o ovim bolesnicima prikupljene su iz njihovih liječničkih kartona kako su isti zabilježeni na bazi podataka u dvije francuske bolnice.
English: In the study of smoke inhalation, the response to Cyanokit was assessed as ‘positive' in 31 patients (45%), ‘partial' in 15 (22%) and ‘absent' in 10 (15%).
Croatian: U ispitivanju udisanja dima, odgovor na Cyanokit ocijenjen je kao "pozitivan" u 31 bolesnika (45%), "djelomičan" u 15 (22%) i "odsutan" u 10 (15%).
English: Cyanokit hydroxocobalamin
Croatian: Cyanokit hidroksokobalamin
English: Hydroxocobalamin (vitamin B12a) has been used as a vitamin supplement since the 1950s.
Croatian: Hidroksokobalamin (vitamin B12a) koristi se kao vitaminski suplement od 1950-tih godina.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Cyanokit on 31 November 2007.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Cyanokit na snazi u Europskoj uniji od 31. studenog 2015.
English: Cyanokit is given as an emergency treatment as soon as possible after poisoning.
Croatian: Cyanokit se primjenjuju kao hitna terapija što je prije moguće nakon trovanja.
English: Other information about Cyanokit
Croatian: Ostale informacije o lijeku Cyanokit
English: Because hydroxocobalamin has an intense red colour, most patients will have dark red colouring of the skin and mucous membranes for up to 15 days and of the urine for up to 35 days after receiving Cyanokit.
Croatian: Budući da hidroksokobalamin ima intenzivnu crvenu boju, većina će bolesnika imati tamno crvenu boju kože i membrana sluznice do 15 dana te će njihov urin promijeniti boju do 35 dana nakon terapije lijekom Cyanokit.
English: This is a summary of the European public assessment report (EPAR) for Cyanokit.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Cyanokit.
English: In this study, the patients' condition at the accident scene was compared with that at the end of the infusion of Cyanokit and over the following three days.
Croatian: U ovom ispitivanju, stanje bolesnika na mjestu nesreće uspoređeno je s onim na kraju infuzije lijeka Cyanokit i tijekom tri naredna dana.
English: There is no information available on success rates with other antidotes for cyanide poisoning, so it was not possible to carry out a comparison between the success rates seen with Cyanokit and with alternatives.
Croatian: Nema dostupnih informacija o broju uspješnih slučajeva s drugim protuotrovima za trovanje cijanidom, tako da nije moguće izvršiti usporedbu između stope uspješnosti uočene s lijekom Cyanokit i drugim alternativama.
English: There have been no studies directly comparing Cyanokit to any other treatment in humans.
Croatian: Ne postoje ispitivanja koja izravno uspoređuju Cynokit s bilo kojom drugom terapijom u ljudi.
English: A sticker explaining this is supplied with every pack of Cyanokit.
Croatian: Naljepnica koja pojašnjava ovo, isporučuje se sa svakim paketom lijeka Cyanokit.
English: What measures are being taken to ensure the safe and effective use of Cyanokit?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Cyanokit?
English: The use of Cyanokit can interfere with the assessment of burns and with laboratory test results.
Croatian: Primjena lijeka Cyanokit može interferirati s ocjenom opeklina i s rezultatima laboratorijskog testiranja.
English: Cyanide poisoning usually results from exposure to smoke from fire, from breathing or swallowing cyanide, or from getting it onto the skin or mucous membranes (moist body surfaces, such as the lining of the mouth).
Croatian: Trovanje cijanidom najčešće je rezultata izlaganju dimu od požara, disanja ili gutanja cijanida ili ulaženja pod kožu ili membrane sluznice (vlažne tjelesne površine, poput ovojnice usta).
English: Information on its effectiveness was obtained in 83 patients who had been admitted to hospital with suspected cyanide poisoning and who received Cyanokit.
Croatian: Informacije o djelotvornosti lijeka prikupljene su u 83 bolesnika koji su primljeni u bolnicu sa sumnjom na trovanje cijanidom i primili su Cyanokit.
English: It contains the active substance hydroxocobalamin (vitamin B12a).
Croatian: Sadrži djelatnu tvar hidroksikobalamin (vitamin B12a).
English: Cyanokit is used as an antidote to treat known or suspected poisoning with cyanide, a highly poisonous chemical.
Croatian: Cyanokit se koristi kao protuotrov za liječenje dokazanog ili suspektnog trovanja cijanidom, vrlo otrovne kemikalije.
English: However, the CHMP concluded that Cyanokit had advantages over alternative antidotes because it has a good safety profile in patients who have not been poisoned.
Croatian: No, CHMP je zaključio da Cyanokit ima prednost u odnosu na alternativne protuotrove budući da ima dobar sigurnosni profil u bolesnika koji nisu otrovani.
English: This can be attached to the patient's notes so that hospital staff are made aware of these effects of the medicine.
Croatian: Ova se naljepnica može zalijepiti na karton bolesnika tako da se bolničkom osoblju skrene pozornost na ovo djelovanje lijeka.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cyanokit.
Croatian: Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka Cyanokit.
English: This helps to reduce the effects of cyanide poisoning.
Croatian: Ovo pomaže pri smanjivanju djelovanja trovanja cijanidom.
English: Cyanokit is given along with other appropriate decontamination and supportive measures, including providing oxygen for the patient to breathe.
Croatian: Cyanokit se primjenjuje zajedno s drugim odgovarajućim mjerama za dekontaminaciju i potpornim mjerama, uključujući isporuku kisika za bolesnike da mogu disati.
English: A further 14 patients were studied whose cyanide poisoning was due to something other than smoke inhalation; most of these patients had taken cyanide during a suicide attempt.
Croatian: Ispitano je daljnjih 14 bolesnika čije je trovanje cijanidom bilo uzrokovano nečim drugim izuzev udisanja dima; većina ovih bolesnika uzelo je cijanid tijekom pokušaja samoubojstva.
English: A risk management plan has been developed to ensure that Cyanokit is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Cyanokit.
English: In one study of 69 patients, cyanide poisoning was due to exposure to smoke from fire.
Croatian: U jednom ispitivanju koje je obuhvatilo 69 bolesnika, trovanje cijanidom uzrokovano izlaganjem dimu od požara.
English: Survival was more likely in those who received Cyanokit before their hearts had stopped, who had less severe symptoms of brain damage and who had lower blood cyanide levels.
Croatian: Preživljavanje je bilo izglednije u onih bolesnika koji su primili Cyanokit prije nego što je njihovo srce prestalo kucati, koji su imali manje ozbiljne simptome oštećenja možda te koji su imali niže koncentracije cijanida u krvi.
English: Cyanokit is a powder to be made up into a solution for infusion (drip) into a vein.
Croatian: Cyanokit je prašak za otopinu za infuziju (drip u venu).
English: Two patients survived despite their hearts having stopped before receiving Cyanokit.
Croatian: Dva su bolesnika preživjela usprkos tome što je njihovo srce prestalo kucati prije dobivanja lijeka Cyanokit.
English: The active substance in Cyanokit, hydroxocobalamin, reacts with cyanide in the body to form cyanocobalamin, a non-poisonous compound that is removed from the body in the urine.
Croatian: Djelatna tvar lijeka Cyanokit, hidroksikobalamin, djeluje s cijanidom u tijelu i tvori cijanokobalamin, neotrovni spoj koji se uklanja iz tijela putem urina.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Cyanokit, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Cyanokit nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: Of the 14 patients whose cyanide exposure was due to something other than smoke inhalation, 10 survived, including seven patients with ‘lethal' levels of cyanide in the blood.
Croatian: Od ukupno 14 bolesnika čije je izlaganje cijanidom bilo uslijed nekog drugog uzroka a ne udisanja dima, 10 ih je preživjelo, uključujući sedam bolesnika sa "smrtonosnim" koncentracijama cijanida u krvi.
English: The full EPAR for Cyanokit can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjelovito Europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) za lijek Cyanokit nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports Više informacija o terapiji lijekom Cyanokit pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: This lowers cyanide levels in the body and stops the cyanide fixing itself to an enzyme in cells called cytochrome oxidase, which is important for providing energy in cells.
Croatian: Ovo smanjuje koncentracije cijanida u tijelu i zaustavlja vezivanje cijanida na enzimom u stanicama naziva citokrom oksidaza, koji je važan za osiguravanje energije u stanicama.
English: Why has Cyanokit been approved?
Croatian: Zašto je Cyanokit odobren?
English: What is Cyanokit?
Croatian: Što je Cyanokit?
English: What is the risk associated with Cyanokit?
Croatian: Koji su rizici povezani s lijekom Cyanokit?
English: This makes it a useful option when cyanide poisoning is only suspected.
Croatian: To ga čini korisnom opcijom u slučaju sumnje na trovanje cijanidom.
English: The four who died had high blood levels of cyanide, and either their hearts had stopped or they had stopped breathing before receiving Cyanokit.
Croatian: Četvero preminulih bolesnika imalo je visoke koncentracije cijanida u krvi, te su njihova srca prestala kucati ili su prestali disati prije nego što su primili lijek Cyanokit.
English: The frequency of the other side effects of Cyanokit cannot be estimated with the information currently available.
Croatian: Učestalost nuspojava lijeka Cyanokit ne može se procijeniti na temelju trenutno dostupnih informacija.
English: Therefore, the CHMP decided that Cyanokit's benefits are greater than its risks and recommended that it be given marketing authorisation.
Croatian: CHMP je odlučio da koristi od lijeka Cyanokit nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za stavljanje lijeka u promet.
English: For the full list of all side effects reported with Cyanokit, see the package leaflet.
Croatian: Potpuni popis svih nuspojava zabilježenih pri primjeni lijeka Cyanokit potražite u uputi o lijeku.
English: What is Cyanokit used for?
Croatian: Za što se Cyanokit koristi?
English: For adults, the initial dose is 5 g. For children, it is 70 mg per kilogram body weight up to a maximum dose of 5 g. A second dose can be given, depending on how severe the poisoning is and how well the patient is responding.
Croatian: U slučaju djece, ista doza iznosi 70 mg po kilogramu tjelesne težine do maksimalne doze od 5 g.
English: What benefit has Cyanokit shown during the studies?
Croatian: Koje su koristi lijeka Cyanokit utvrđene u ispitivanjima?
English: The CHMP concluded that Cyanokit appeared to be a well-tolerated and efficient cyanide antidote, based on its effects on survival and the prevention of brain damage.
Croatian: CHMP je zaključio na temelju djelovanja lijeka na preživljavanje i prevenciju oštećenja mozga kako se čini da se Cyanokit dobro podnosi i da je djelotvoran protuotrov za cijanid.
English: How does Cyanokit work?
Croatian: Kako djeluje Cyanokit?
English: How is Cyanokit used?
Croatian: Kako se Cyanokit koristi?
English: How has Cyanokit been studied?
Croatian: Kako je Cyanokit ispitivan?
English: Whereas,
Croatian: Nadalje,
English: The CHMP took these comments into account.
Croatian: CHMP je uzeo u obzir ove primjedbe.
English: The applicant presented literature search strategy.
Croatian: Podnositelj zahtjeva predstavio je strategiju pretraživanja literature.
English: The reference Member State (RMS) is the United Kingdom and the concerned Member States (CMS) Austria (AT), Germany (DE), Croatia (HR), Ireland (IE), Luxembourg (LU), France (FR), Belgium (BE), Netherlands (NL), Portugal (PT) and Spain (ES).
Croatian: Referentna država članica (RMS) je Ujedinjena Kraljevina, a države članice sudionice u postupku (CMS) su Austrija (AT), Njemačka (DE), Hrvatska (HR), Irska (IE), Luksemburg (LU), Francuska (FR), Belgija (BE), Nizozemska (NL), Portugal (PT) i Španjolska (ES).
English: The decentralised procedures UK/H/6034/001/DC, UK/H/6035/001/DC and UK/H/6176/001/DC started on 23 July 2015.
Croatian: Decentralizirani postupci UK/H/6034/001/DC, UK/H/6035/001/DC i UK/H/6176/001/DC pokrenuti su 23. srpnja 2015.
English: Linear interpolation was use to estimate intermittent missing values.
Croatian: Linearna interpolacija korištena je za procjenu nestalnih vrijednosti koje nedostaju.
English: They all seem numerically similar to each other; however no formal comparison between the active substances was performed.
Croatian: Sve se one čine numerički sličnima, ali službena usporedba aktivnih sastojaka nije provedena.
English: A risk management plan has been submitted in line with the above.
Croatian: Plan upravljanja rizikom podnesen je u skladu s gore navedenim.
English: More importantly this is consistent with the post marketing experience of the use of the combination both world-wide and in the countries within the EU.
Croatian: Što je još važnije, to je u skladu s iskustvom nakon stavljanja kombinacije na tržište diljem svijeta i u zemljama EU-a.
English: These risks are well known and are controlled by routine pharmacovigilance practices which CHMP has endorsed.
Croatian: Ti su rizici dobro poznati te se kontroliraju rutinskim farmakovigilancijskim praksama koje je odobrio CHMP.
English: Risk management
Croatian: Upravljanje rizikom
English: • The Committee considered the notification of the referral initiated by the United Kingdom under Article 29(4) of Directive 2001/83/EC on the basis that France, Germany, Spain and The Netherlands considered that the granting of the marketing authorisation would constitute a potential serious risk to public health.
Croatian: • Odbor je razmotrio obavijest o arbitražnom postupku koji je pokrenula Ujedinjena Kraljevina u skladu s člankom 29. stavkom 4. Direktive 2001/83/EZ na temelju toga da su Francuska, Njemačka, Španjolska i Nizozemska smatrale da bi izdavanje odobrenja za stavljanje lijeka u promet predstavljalo potencijalan ozbiljan rizik za javno zdravlje.
English: It is noted that there is significant use of opioid combinations in the EU.
Croatian: Poznato je da u EU-u postoji znatna primjena raznih kombinacija opioida.
English: This medicinal product is already authorised during the first and second waves of the decentralised procedure as prescription only medicine in many EU countries.
Croatian: Lijek je već odobren za vrijeme prve i druge faze decentraliziranog postupka kao lijek koji se izdaje isključivo na recept u mnogim zemljama EU-a.
English: All the risks associated with prolonged use have been identified as safety concerns in the current risk management plan.
Croatian: Svi rizici povezani s produženom primjenom utvrđeni su kao sigurnosna pitanja u postojećem planu upravljanja rizikom.
English: As at the CMDh procedure no agreement could be reached the procedure was referred to the CHMP.
Croatian: Budući da u postupku pri CMDh-u nije postignut dogovor, postupak je upućen Odboru za lijekove za humanu uporabu (CHMP).
English: Based on clinical data provided by the applicant, no new safety issues have been identified.
Croatian: Na temelju kliničkih podataka koje je dostavio podnositelj zahtijeva nisu utvrđena nikakva sigurnosna pitanja.
English: It is worth noting that the indication being sought is for short term (3 days) exposure.
Croatian: Važno je istaknuti da se zahtijeva indikacija za kratkoročno (trodnevno) izlaganje.